Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:2.7.7.8 (
polynucleotide phosphorylase
)
723
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Mitochondria are descendants of endosymbiotic bacteria and retain essential prokaryotic features such as a compact circular genome. Consequently, in mammals, mitochondrial DNA is subjected to bidirectional transcription that generates overlapping transcripts, which are capable of forming long double-stranded RNA structures
1,2
. However, to our knowledge, mitochondrial double-stranded RNA has not been previously characterized in vivo. Here we describe the presence of a highly unstable native mitochondrial double-stranded RNA species at single-cell level and identify key roles for the degradosome components mitochondrial RNA helicase SUV3 and
polynucleotide phosphorylase
PNPase
in restricting the levels of mitochondrial double-stranded RNA. Loss of either enzyme results in massive accumulation of mitochondrial double-stranded RNA that escapes into the cytoplasm in a
PNPase
-dependent manner. This process engages an MDA5-driven antiviral signalling pathway that triggers a type I interferon response. Consistent with these data, patients carrying hypomorphic mutations in the gene PNPT1, which encodes
PNPase
, display mitochondrial double-stranded RNA accumulation coupled with upregulation of
interferon
-stimulated genes and other markers of immune activation. The localization of
PNPase
to the mitochondrial inter-membrane space and matrix suggests that it has a dual role in preventing the formation and release of mitochondrial double-stranded RNA into the cytoplasm. This in turn prevents the activation of potent innate immune defence mechanisms that have evolved to protect vertebrates against microbial and viral attack.
...
PMID:Mitochondrial double-stranded RNA triggers antiviral signalling in humans. 3020 36
PNPT1
(
PNPase
-
polynucleotide phosphorylase
) is involved in multiple RNA processing functions in the mitochondria. Bi-allelic pathogenic
PNPT1
variants cause heterogeneous clinical phenotypes affecting multiple organs without any established genotype-phenotype correlations. Defects in
PNPase
can cause variable combined respiratory chain complex defects. Recently, it has been suggested that
PNPase
can lead to activation of an innate immune response. To better understand the clinical and molecular spectrum of patients with bi-allelic
PNPT1
variants, we captured detailed clinical and molecular phenotypes of all 17 patients reported in the literature, plus seven new patients, including a 78-year-old male with the longest reported survival. A functional follow-up of genomic sequencing by cDNA studies confirmed a splicing defect in a novel, apparently synonymous, variant. Patient fibroblasts showed an accumulation of mitochondrial unprocessed
PNPT1
transcripts, while blood showed an increased
interferon
response. Our findings suggest that functional analyses of the RNA processing function of
PNPase
are more sensitive than testing downstream defects in oxidative phosphorylation (OXPHPOS) enzyme activities. This research extends our knowledge of the clinical and functional consequences of bi-allelic pathogenic
PNPT1
variants that may guide management and further efforts into understanding the pathophysiological mechanisms for therapeutic development.
...
PMID:Clinical Spectrum and Functional Consequences Associated with Bi-Allelic Pathogenic
PNPT1
Variants. 3175 25
<< Previous
1
2